These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 27263780)

  • 1. [Mechanisms of drug resistance and sensitivity concerning novel agents for multiple myeloma].
    Tokuhira M
    Rinsho Ketsueki; 2016 May; 57(5):563-74. PubMed ID: 27263780
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting Intrinsic and Extrinsic Vulnerabilities for the Treatment of Multiple Myeloma.
    Anreddy N; Hazlehurst LA
    J Cell Biochem; 2017 Jan; 118(1):15-25. PubMed ID: 27261328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenetic mechanisms of cell adhesion-mediated drug resistance in multiple myeloma.
    Furukawa Y; Kikuchi J
    Int J Hematol; 2016 Sep; 104(3):281-92. PubMed ID: 27411688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug resistance in multiple myeloma.
    Robak P; Drozdz I; Szemraj J; Robak T
    Cancer Treat Rev; 2018 Nov; 70():199-208. PubMed ID: 30245231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting the Pim kinases in multiple myeloma.
    Keane NA; Reidy M; Natoni A; Raab MS; O'Dwyer M
    Blood Cancer J; 2015 Jul; 5(7):e325. PubMed ID: 26186558
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contemporary drug therapies for multiple myeloma.
    de la Puente P; Azab AK
    Drugs Today (Barc); 2013 Sep; 49(9):563-73. PubMed ID: 24086952
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted therapy of multiple myeloma based upon tumor-microenvironmental interactions.
    Anderson KC
    Exp Hematol; 2007 Apr; 35(4 Suppl 1):155-62. PubMed ID: 17379101
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tipifarnib and bortezomib are synergistic and overcome cell adhesion-mediated drug resistance in multiple myeloma and acute myeloid leukemia.
    Yanamandra N; Colaco NM; Parquet NA; Buzzeo RW; Boulware D; Wright G; Perez LE; Dalton WS; Beaupre DM
    Clin Cancer Res; 2006 Jan; 12(2):591-9. PubMed ID: 16428505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular mechanisms in multiple myeloma drug resistance.
    Nikesitch N; Ling SC
    J Clin Pathol; 2016 Feb; 69(2):97-101. PubMed ID: 26598624
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanisms of Drug Resistance in Relapse and Refractory Multiple Myeloma.
    Yang WC; Lin SF
    Biomed Res Int; 2015; 2015():341430. PubMed ID: 26649299
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigenetic strategies to reverse drug resistance in heterogeneous multiple myeloma.
    Issa ME; Takhsha FS; Chirumamilla CS; Perez-Novo C; Vanden Berghe W; Cuendet M
    Clin Epigenetics; 2017; 9():17. PubMed ID: 28203307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Role of Intracellular Signaling Pathways in the Pathogenesis of Multiple Myeloma and Novel Therapeutic Approaches.
    Kizaki M; Tabayashi T
    J Clin Exp Hematop; 2016; 56(1):20-7. PubMed ID: 27334854
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NEDD8 Inhibition Overcomes CKS1B-Induced Drug Resistance by Upregulation of p21 in Multiple Myeloma.
    Huang J; Zhou Y; Thomas GS; Gu Z; Yang Y; Xu H; Tricot G; Zhan F
    Clin Cancer Res; 2015 Dec; 21(24):5532-42. PubMed ID: 26156395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiple myeloma and persistence of drug resistance in the age of novel drugs (Review).
    Krishnan SR; Jaiswal R; Brown RD; Luk F; Bebawy M
    Int J Oncol; 2016 Jul; 49(1):33-50. PubMed ID: 27175906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug resistance and drug development in multiple myeloma.
    Dalton WS
    Semin Oncol; 2002 Dec; 29(6 Suppl 17):21-5. PubMed ID: 12520481
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting of adhesion molecules as a therapeutic strategy in multiple myeloma.
    Neri P; Bahlis NJ
    Curr Cancer Drug Targets; 2012 Sep; 12(7):776-96. PubMed ID: 22671924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dissecting the multiple myeloma-bone microenvironment reveals new therapeutic opportunities.
    Shay G; Hazlehurst L; Lynch CC
    J Mol Med (Berl); 2016 Jan; 94(1):21-35. PubMed ID: 26423531
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer stem cells are the cause of drug resistance in multiple myeloma: fact or fiction?
    Franqui-Machin R; Wendlandt EB; Janz S; Zhan F; Tricot G
    Oncotarget; 2015 Dec; 6(38):40496-506. PubMed ID: 26415231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel therapeutic strategies for multiple myeloma.
    Mimura N; Hideshima T; Anderson KC
    Exp Hematol; 2015 Aug; 43(8):732-41. PubMed ID: 26118499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bone Marrow Stromal Cells-Induced Drug Resistance in Multiple Myeloma.
    Ria R; Vacca A
    Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31963513
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.